HC Wainwright & Co. Maintains Buy on Can Fite Biopharma, Raises Price Target to $5
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) with a Buy and raises the price target from $2.5 to $5.